Abstract YO36
Case summary
The frequency of BRAF mutation in non-small-cell lung cancer (NSCLC) is 1–2%. Some studies showed the patients with the mutation have poor outcomes to chemotherapy. Use of dabrafenib plus trametinib in BRAF V600E mutated NSCLC showed improvement in clinical outcomes of treatment-naïve and previously treated patients in phase II trials.
Pulmonary pleomorphic carcinoma (PPC) is a rare histologic subtype of NSCLC characterized by aggressive features with poor prognosis. Many of PPCs are reported to be resistant to chemotherapy and radiotherapy. Some types of targetable oncogenes have been detected in PPCs. However, the significance of BRAF mutation in PPC remains unclear.
Here we describe a patient with BRAF V600E mutated NSCLC with pleomorphic feature treated with BRAF and MEK inhibitor.
The patient is a 53-year-old woman. Chest CT scan revealed the mass invading the chest wall in the right middle lobe, hilar and mediastinal lymph node metastasis, and pleural dissemination. Biopsy from the primary tumor showed NSCLC-NOS. Gene analysis revealed the tumor was EGFR wild type, ALK/ROS-1 fusion negative, and PD-L1 TPS was 0%. Clinical stage was T4 N2 M1a, Stage IVA.
She received CDDP+GEM, Pemetrexed, and TS-1 sequentially, however, no response was obtained by these therapies. At the time of disease progression, right middle and lower lobe atelectasis was caused by the primary tumor and lymph nodes enlargement, and multiple bone metastasis emerged.
Re-biopsy was performed from the chest wall invasion site. The sample showed poor differentiated epithelial tumor cells and spindle cells suggesting pleomorphic feature and BRAF V600E was detected by next generation sequencing test.
Based on the result, we started dabrafenib plus trametinib therapy. The primary lesion and hilar lymph nodes rapidly shrunk resulting in atelectasis resolving on the chest X-ray in two weeks. The CT scan revealed dramatic tumor response in all metastatic legions. The response continued for about 10 months.
To best of our knowledge, few BRAF mutation positive NSCLC with pleomorphic feature cases have been reported. This case suggests that BRAF V600E mutation is also an important therapeutic target in PPC as much as in other histology.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
174P - Progression of computer aided diagnosis on gastric cancer
Presenter: Yingyan Yu
Session: Poster display session
Resources:
Abstract
175P - Hypermethylation of the PCDHB15 promoter predicts the prognosis in gastric cancer
Presenter: Yu-ting Lee
Session: Poster display session
Resources:
Abstract
176P - DCLK1 promotes tumour invasion and metastasis through epithelial-mesenchymal transition and the MEK/ERK pathway in esophageal squamous cell carcinoma
Presenter: Jiannan Yao
Session: Poster display session
Resources:
Abstract
177P - Comparison of nab-paclitaxel plus ramcirumab and paclitaxel plus ramcirumab in patients with pretreated metastatic gastric cancer
Presenter: Yosuke Horita
Session: Poster display session
Resources:
Abstract
178P - Chief cell in stomach have stem cell activity and potential to develop gastric cancer
Presenter: Akihiro Yamamura
Session: Poster display session
Resources:
Abstract
179P - Postoperative Adjuvant transarterial chemoembolization versus surgery alone for resected hepatocellular carcinoma: A propensity-score matching study
Presenter: Mingyu Chen
Session: Poster display session
Resources:
Abstract
180P - LHPP inhibit the cell proliferation and EMT via the TGFβ/SMAD3 signaling pathway in iCCA
Presenter: Dan Wang
Session: Poster display session
Resources:
Abstract
181P - The emerging role of third-line gemcitabine plus nab-paclitaxel in advanced pancreatic adenocarcinoma
Presenter: Andrew Dean
Session: Poster display session
Resources:
Abstract
182P - Durable response to second-line m-FOLFIRINOX for advanced pancreatic adenocarcinoma in patients with performance status of two or less
Presenter: Adarsh Das
Session: Poster display session
Resources:
Abstract
183P - Epidemiologic profile of gastric cancer in East Azerbaijan, Iran: 2 years population-based cancer registry results
Presenter: Pooneh Jabbaripour
Session: Poster display session
Resources:
Abstract